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Dipeptidyl peptidase (DPP)-4 plays an important role in endothelial cell biology. We have shown that the
DPP-4 inhibitor Linagliptin can inhibit the endothelial-mesenchymal transition (EndMT) and ameliorate
diabetic kidney ﬁbrosis associated with the suppression of DPP-4 protein levels via the induction of miR-
29. The current study demonstrated that such effects of Linagliptin on endothelial cell proﬁbrotic pro-
grams were drug-speciﬁc but not class effects. In the cell-free system, both Linagliptin and Sitagliptin
inhibited recombinant DPP-4 activity in a concentration-dependent manner. Linagliptin can inhibit all of
the following: DPP-4 activity and protein level, integrin b1 protein levels, EndMT, and DPP-4 30UTR ac-
tivity; Sitagliptin, however, inhibited none of these in the current study. Additionally, TGF-b2 induced
both the induction of VEGF-R1 and the suppression of VEGF-R2 levels in endothelial cells, and both were
inhibited by Linagliptin but not by Sitagliptin. miR-29, the miR that negatively regulates the 30UTR of
DPP-4 mRNA, was suppressed by TGF-b2 and restored by Linagliptin but not by Sitagliptin. Following the
overexpression of pCMV-DPP-4-GFP and pCMV6-Myc-DPP-4 in endothelial cells, the proximity of Myc-
DPP-4 and DPP-4-GFP was suppressed by Linagliptin but not by Sitagliptin, suggesting that only Lina-
gliptin inhibited the homo-dimer formation of DPP-4 in endothelial cells; this difference in activity
between the two gliptins could explain their diverse effects on endothelial cell biology. In conclusion,
each of the DPP-4 inhibitors may have unique drug-speciﬁc effects.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dipeptidyl peptidase IV (DPP-4), also known as CD26, is awidely
expressed serine peptidase that exists on the surface of various cell
types, including endothelial cells, kidney epithelial cells, and Tcells,
which express binding proteins and transmit intracellular signals
[1,2]. Transmembrane and soluble forms of DPP-4 preferentially
cleave dipeptides from the amino terminus of polypeptides with a
proline or alanine at the second position [3]. In addition to its& Endocrinology, Kanazawa
pan.
& Endocrinology, Kanazawa
pan.
(K. Kanasaki), koya0516@
Inc. This is an open access article uexopeptidase activity, DPP-4 also functions as a binding protein and
is highly accessible to peptide substrates circulating through the
gut, liver, lung, and kidney [4]. The kidney is the organ in which
DPP-4 is expressed at the highest level per organ weight [5].
DPP-4 is a well-documented drug target for the treatment of
type 2 diabetes because the incretin hormones, glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP), are the substrates of DPP-4 [6e8]. Sitagliptin is the most
commonly used DPP-4 inhibitor, as it was the ﬁrst DPP-4 inhibitor
launched worldwide and therefore beneﬁts from the most exten-
sive clinical experience; Linagliptin represents the recently world
widely approved product in this class of anti-diabetic drugs, and no
dosage adjustment is required in patients with renal impairment.
Both Linagliptin and Sitagliptin act by inhibiting the catalytic ac-
tivity of the DPP-4 enzyme that rapidly inactivates the intestinal
hormone, GLP-1. There are several differences between the DPP-4nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and elimination, as well as in their potency and durations of action
[9,10]. These inhibitors are all small molecules that are rapidly
absorbed following oral dosing, resulting in over 80% inhibition of
DPP-4 activity for the full 24-h period. They typically raise the
peripheral plasma concentration of the intact forms of both incre-
tins by two-to three-fold. Although the class differs widely in terms
of chemistry, all of the inhibitors are selective for DPP-4 [11] in their
clinical doses.
Takai et al. reported that in Zucker diabetic fatty rats, Sitagliptin
(10 mg/kg per day) and Linagliptin (3 mg/kg per day) displayed
similar blood glucose and plasma insulin levels; however, DPP-4
activity in both plasma and vascular tissues were signiﬁcantly
lower in the Linagliptin-treated rats compared with the rats in the
Sitagliptin-treated group [12]. These data indicated that different
gliptins may display different effects. We have conﬁrmed that DPP-
4 plays a vital role in endothelial cell biology. The suppression of
DPP-4 activity by Linagliptin was associated with the amelioration
of kidney ﬁbrosis, the suppression of TGFb/smad signaling and
endothelial-to-mesenchymal transition (EndMT), and the induc-
tion of microRNA 29s [13]. Furthermore, Linagliptin inhibited DPP-4
and integrin b1 interactions associated with enhanced endothelial
survival signaling mediated through vascular endothelial growth
factor signaling [14]. These data clearly demonstrated that DPP-4
inhibition by Linagliptin restored endothelial homeostasis that
was insulted by hyperglycemia. However, whether such potential
effects of Linagliptin are DPP-4 inhibitor class- or Linagliptin-
speciﬁc remains unclear. Here, we hypothesized that Linagliptin
and Sitagliptin exhibit different speciﬁc effects in endothelial cells.2. Materials and methods
2.1. Reagents and antibodies
Linagliptin was provided by Boehringer-Ingelheim under MTA
(material transfer agreement). Sitagliptin was from Sequoia, UK.
Mouse monoclonal anti-human CD31 and goat polyclonal anti-
human TGF-bR2 antibodies were purchased from R&D Systems
(Minneapolis, MN). A rabbit polyclonal anti-phospho-smad3 (s423
and s425) antibody was purchased from Rockland Immunochem-
icals (Gilbertsville, PA). A rabbit polyclonal anti-aSMA antibodywas
purchased from GeneTex (Irvine, CA). Goat polyclonal anti-DPP-4
(for Western blot analysis of human cells), rabbit polyclonal anti-
TGF-b receptor 1 antibody, mouse monoclonal and anti-b-actin
antibodies were obtained from Sigma (St. Louis, MO). Rabbit poly-
clonal anti-integrin b1 (phospho T788 þ T789) and rabbit poly-
clonal anti-VEGFR2 antibodies were purchased from Abcam
(Cambridge, UK). A rabbit polyclonal anti-Flt1 (VEGFR1) antibody
was purchased from Santa Cruz Biotechnology (Dallas, TX). Fluo-
rescence-, Alexa Fluor 647-, and rhodamine-conjugated secondary
antibodies were obtained from Jackson ImmunoResearch (West
Grove, PA). TGF-b2 was purchased from PeproTech (Rocky Hill, NJ).2.2. Endothelial cell culture and DPP-4 inhibitor treatment
Human dermal microvascular endothelial cells (HMVECs, Lonza,
Basel, Switzerland) cultured in EGM medium supplemented with
EGM™-2 were used in this experiment. When the HMVECs reached
70% conﬂuence, 5 ng/ml recombinant human TGF-b2 was placed in
the experimental medium (HuMedia-MVG in serum-free RPMI at a
1:3 ratio) for 48 h with or without Linagliptin (25, 50, and 100 nM)
or Sitagliptin (0.5 mM, 2 mM, 5 mM, 25 mM, 50 mM, and 100 mM)
preincubation for 1 h. The vehicle (DMSO) was added to the control
well.2.3. DPP-4 activity measurement
DPP-4 enzymatic activity was analyzed using a DPP-IV Activity
Assay Kit (Biovision, Milpitas, CA). For the cell system, cells were
homogenized in DPP-4 assay buffer and centrifuged at 13,000  g
for 10min to remove insolublematerial. The samples were adjusted
to a ﬁnal volume of 50 ml and added to a 96-well plate for analysis.
For the cell-free system, 0.5 mg/ml recombinant human DPP-4 (R&D
Systems, Minneapolis, MN) were diluted in 50 ml of DPP-4 assay
buffer and then treated with Linagliptin or Sitagliptin for 2 h at
37 C. All of the samples were mixed with 2 ml of the Gly-Pro-7-
Amino-4-Methylcoumarin (AMC) substrate and then incubated at
37 C for 30 min. The release of AMC from the substrate was
measured with a ﬂuorescence spectrophotometer at an excitation
of 360 nm and emission of 460 nm.
2.4. Immunoﬂuorescence
Cells cultured in an 8-well chamber were used for DPP-4
immunoﬂuorescence. Brieﬂy, after being washed in PBS 3 times,
the cells were placed in methanol for 10 min at 20 C and then in
acetone for 1 min at 20 C. Next, they were washed 3 times in PBS
for 5 min and blocked in 2% BSA/PBS for 30 min at room temper-
ature. Afterward, the cells were incubated in a primary antibody for
1 h and washed in PBS 3 times (5 min each time). Subsequently, the
cells were incubated with the secondary antibodies for 30 min,
washedwith PBS 3 times (5min each) andmountedwithmounting
mediumwith DAPI (Vector Laboratories, Burlingame, CA, USA). The
immunolabeled cells were analyzed with ﬂuorescence microscopy
(Axio Vert.A1, Carl Zeiss Microscopy GmbH, Jena, Germany). For
each group, 300 magniﬁcation pictures were obtained from 6
different areas.
2.5. Western blot analysis
The protein lysates were denatured by boiling in sodium
dodecyl sulfate (SDS) sample buffer at 94 C for 5 min and then
centrifuged at 15,000  g for 15 min at 4 C. Next, the supernatant
was separated on SDS-polyacrylamide gels. The separated protein
on the gels were transfered onto PVDF membranes (Pall Corpora-
tion, Pensacola, FL) via the semidry method. After blocking with
TBST (Tris-buffered saline containing 0.05% Tween 20) containing
5% BSA, the membranes were incubated with the primary anti-
bodies of the target molecules (1:1000 for primary antibodies;
1:10,000 for b-actin) at 4 C overnight. The membranes were
washed 3 times and incubated with HRP-conjugated secondary
antibodies (1:2000; 1:7500 for DPP-4) for 1 h at room temperature.
The immunoreactive bands were visualized with an enhanced
chemiluminescence (ECL) detection system (Pierce Biotechnology,
Rockford, IL) by the ImageQuant LAS 400 camera system (GE
Healthcare Life Sciences, Uppsala, Sweden).
2.6. MicroRNA isolation and qPCR
MicroRNA was extracted using miRNeasy Mini kit (Qiagen, Hil-
den, Germany) according to the manufacturer's instructions for
homogenized samples. The complementary DNA was generated by
a miScript II RT kit (Qiagen) using the hiSpec buffer method. The
microRNA expression was quantiﬁed using a miScript SYBR Green
PCR Kit (Qiagen) using 3 ng of complementary DNA. The primers to
quantify Mm_miR-29a, Mm_miR-29b, and Mm_miR-29c were the
miScript primer assays pre-designed by Qiagen. The mature
microRNA sequences were 50, UAGCACCAUCUGAAAUCGGUUA for
Mm_miR-29a, 50 UAGCACCAUUUGAAAUCAGUGUU for Mm_miR-
29b, and 50 UAGCACCAUUUGAAAUCGGUUA for Mm_miR-29c. All
S. Shi et al. / Biochemical and Biophysical Research Communications 471 (2016) 184e190186experiments were performed in triplicate, and Hs_RNU6-2_1
(Qiagen) was utilized as an internal control.
2.7. Luciferase assay
For the luciferase assay to analyze the activity of 30UTR in human
DPP-4, we cloned the fragment of human DPP-4 30UTR sequence by
PCR using the primer set as described previously [13]. Both the
puriﬁed PCR fragments and pmirGLO Dual-LuciferasemiRNATarget
Expression Vector (Promega) were enzyme digested (Sac-1 and
Xba-1), puriﬁed, and ligated (Thermo Fisher Scientiﬁc, Waltham,
MA). The sequence of DPP-4 30UTR was conﬁrmed, and the
ampliﬁed vector DNA (300 ng/well in a 12-well plate) was trans-
fected into HMVEC. In the presence of the control, TGF-b2 with or
without Linagliptin or Sitagliptin was evaluated in triplicate sam-
ples using the Dual-Luciferase® Reporter (DLR™) Assay System
(Promega).
2.8. DPP-4 overexpression vector construction
The pCMV6-DPP-4-GFP plasmid was purchased from ORIGENE
(Rockville, MD). To generate the pCMV-Myc-DPP-4 plasmid, we
ampliﬁed the full-length DPP-4 cDNA by PCR using the pCMV6-
DPP-4-GFP plasmid as a template and the speciﬁc primer pair
(Fw. 50- C CGA ATT CGG ATG AAG ACA CCG TGG AAG GTT CTT C -30;
Rev 50- AT CTC GAG CTA AGG TAA AGA GAA ACA GTT TTT TAT G -30).
Both the ampliﬁed DPP-4 cDNA and pCMV-Myc cloning vector
(Clontech, Mountain View, CA) were digested with EcoRI and XhoI,
and the resulting product was ligated (TOYOBO, Japan). The ligated
products (pCMV-Myc-DPP-4) were transformed into competent
cells and ampliﬁed, and the sequence was conﬁrmed.
2.9. DNA transfection
For the transfection studies, HMVECs that were maintained in
EBM-2 medium supplemented with EGM™-2 were passaged in 6-
well plates with non-proliferative medium (HuMedia-EB2 and
RPMI-1640 at a ratio of 1:3). The HMVECs were transfected with
500 ng/well of pCMV6-DPP-4-GFP, pCMV-Myc-DPP-4 or control
vector for the overexpression study. The cells were incubated for
6 h with Lipofectamine in antibiotic-free medium; themediumwas
then replaced with fresh experimental medium (HuMedia-MVG
and RPMI-1640 at a ratio of 1:3). After 24 h, the cells were treated
with or without TGF-b2 (5 ng/ml) with or without Linagliptin or
Sitagliptin preincubation for 1 h, after which the samples were
incubated for another 24 h.
2.10. Chemical crosslinking assay
The HMVECs were transfected with pCMV-Myc-DPP-4 cDNA for
24 h and lysed with cell lysis buffer (Cell Signaling Technology,
Danvers, MA, USA) containing 50 mM NaF, 1 mM PMSF and pro-
tease inhibitor cocktail. Next, 2.3% glutaraldehyde was added to the
lysate at a ﬁnal concentration of 5%. The lysate was then incubated
at 37 C for 10min, and 1mM Tris-HCl (PH 7.5) was used to stop the
reaction. The samples were mixed with 2 sample loading buffer
and heated at 100 C for 5 min. The Western blot was performed
using the anti-Myc antibody.
2.11. Duolink in situ assay
The Duolink® in situ kit was utilized to detect the close prox-
imity of Myc/GFP in the experiment as previously described [15].
Brieﬂy, HMVECs were passaged into 8-well Culture Slides (BD
Biosciences, Franklin Lakes, NJ, USA) in EBM-2 mediumsupplemented with EGMTM-2. When the HMVECs reached 70%
conﬂuence, the cells were transfected with pCMV6-DPP-4-GFP,
pCMV-Myc-DPP-4 or control vector. After transfection, the cells
were treated with TGF-b2 (5 ng/ml) with or without Linagliptin or
Sitagliptin for 24 h. The cells were washed with PBS, ﬁxed with 4%
paraformaldehyde and permeabilized with 0.2% Triton-X100.
Subsequently, the blocking solution in the Duolink in situ kit was
used for 30 min at 37 C, after which the cells were incubated in the
primary antibody (mouse polyclonal anti-Myc antibody/rabbit
polyclonal anti-GFP) at 4 C overnight. After the cells were treated
with the two PLA probes for 1 h at 37 C, Ligation-Ligase solution
was added for 30 min at 37 C, and Ampliﬁcation-Polymerase so-
lution was added for 100 min at 37 C. The slides were then
mountedwith DAPI and analyzed by ﬂuorescencemicroscope (Axio
Vert.A1, Carl Zeiss Microscopy GmbH, Jena, Germany) and Confocal
scanning microscope (LSM710, Carl Zeiss Microscopy GmbH, Jena,
Germany). For each slide, pictures were obtained from 6 different
areas, and quantiﬁcation was performed.
2.12. Statistical analysis
The data are expressed as the mean ± standard error of the
mean (SEM). One-way ANOVA and Tukey's multiple comparison
test were used to determine signiﬁcance, which was deﬁned as
P < 0.05 unless otherwise noted. GraphPad Prism software (Ver
5.0f) was used for the statistical analysis.
3. Results
3.1. Sitagliptin did not suppress the DPP-4 activity and protein
levels in endothelial cells
We ﬁrst identiﬁed the concentration of each DPP-4 inhibitor
that exhibited similar DPP-4 inhibitory action in an in vitro cell-free
system. In the cell-free system, both Linagliptin (up to 100 nM) and
Sitagliptin (up to 100 mM) exhibited concentration-dependent
suppression of DPP-4 (0.5 mg/ml in the media) activity compared
with the control group (Fig. 1A). When analyzing the TGF-b2-
induced DPP-4 activity in the endothelial cells (HMVEC), Lina-
gliptin continued to exhibit a trend of dose-dependent inhibitory
effects; Sitagliptin (up to 100 mM) did not suppress DPP-4 activity
compared with TGF-b2-treated HMVEC (Fig. 1B). Because 100 nM
Linagliptin and 5 mM Sitagliptin have similar inhibitory effects on
DPP-4 activity in a cell-free system (Fig. 1A), we chose these two
concentrations for use in the following analysis. Western blot
analysis re-conﬁrmed that Linagliptin suppressed TGF-b2-induced
DPP-4 protein levels [13]; Sitagliptin, however, did not suppress
TGF-b2-induced DPP-4 protein levels in HMVECs (Fig. 1C, D). We
tested whether a higher concentration of Sitagliptin could suppress
TGF-b2-induced DPP-4 protein levels in HMVECs; however, con-
centrations of up to 100 mM Sitagliptin displayed no signiﬁcant
effects on DPP-4 protein levels in HMVECs (Fig. 1E, F). Immuno-
ﬂuorescence analysis further conﬁrmed that Linagliptin, but not
Sitagliptin, suppressed TGF-b2-stimulated DPP-4 protein levels in
HMVECs (Fig. 1G).
The TGF-b2-stimulated luciferase activity of the pmirGLO Dual-
Luciferase miRNA Target Expression Vector inserted a 30UTR frag-
ment of DPP-4 containing a microRNA 29 binding site was signiﬁ-
cantly suppressed by miR-29 mimetics [13]. MiR-29 inhibition
results in the strong induction of DPP-4 30UTR-luciferase activity; in
basal conditions, miR-29a likely emerges as the main regulator of
DPP-4 30UTR [13,16]. In our analysis, TGF-b2-induced DPP-4 30UTR
luciferase activity was suppressed by Linagliptin pre-treatment but
not by Sitagliptin (Fig. 1H). Furthermore, we analyzed the miR-29a-
c level in endothelial cells by qPCR and found that TGF-b2-
Fig. 1. Sitagliptin did not suppress DPP-4 activity or protein levels in endothelial cells. A: DPP-4 activity measurements in the cell-free system. The graphs in the ﬁgure present data
expressed as the means ± SEM. n ¼ 4. B: DPP-4 activity measurements in endothelial cells (HMVECs). The graphs in the ﬁgure present data expressed as the means ± SEM. 5 ng/ml
TGF-b2 was used in the group. n ¼ 6. C: Western blot analysis of DPP-4 in TGF-b2-treated (5 ng/ml) HMVECs with or without Linagliptin (100 nM) or Sitagliptin (5 mM). Repre-
sentative blot from 4 independent experiments is shown. D: Densitometric analysis of the DPP-4 level normalized with actin. n ¼ 4 in each group analyzed. Data are expressed as
the means ± SEM in the graph. E: Western blot analysis of DPP-4 in TGF-b2-treated (5 ng/ml) HMVECs with or without Linagliptin (25, 50, and 100 nM) or Sitagliptin (0.5, 2, 5, 25, 50
and 100 mM). Representative results from 3 independent analyses are shown. F: Densitometric analysis of the DPP-4 level normalized with actin. n ¼ 4 in each group analyzed. Data
are expressed as the means ± SEM in the graph. G: Immunoﬂuorescence analysis of DPP-4 in HMVECs. The original magniﬁcation was 300. Scale bar: 50 mm in each panel.
Representative pictures from 3 different well cells are shown. 5 ng/ml TGF-b2 was used in the group. H: DPP-4 30UTR transcriptional activity measurement in TGF-b2-treated (5 ng/
ml) HMVECs with or without Linagliptin (100 nM) or Sitagliptin (5 mM). Experiments were performed 3 times, yielding similar results. IeK: Gene expression analysis of miR-29s in
TGF-b2-treated (5 ng/ml) HMVECs with or without Linagliptin (100 nM) or Sitagliptin (5 mM). N ¼ 6 were analyzed in each data set. The data are expressed as the means ± SEM and
are included in the graph. I: miR-29a; J: miR-29b; K: miR-29c.
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but not by Sitagliptin (Fig. 1IeK).
3.2. TGF-b2-induced EndMT and TGF-b2-induced proﬁbrotic
signaling was not inhibited by Sitagliptin
In our previous reports, we showed that Linagliptin inhibited
endothelial-mesenchymal transition (EndMT) in streptozotocin-
induced type 1 diabetic mice and TGF-b2-stimulated HMVECs
[13,14]. Similarly, in the present study, Linagliptin inhibited TGF-b2-
induced EndMT (suppression of endothelial marker CD31 with
concomitant induction of mesenchymal marker a-smooth muscle
actin) (Fig. 2AeC); Sitagliptin exhibited no inﬂuence on the TGF-b2-
induced EndMT (Fig. 2AeC). We also conﬁrmed that, unlike Lina-
gliptin, Sitagliptin did not inhibit TGF-b2-induced Smad3 phos-
phorylation or TGF-bR1/2 protein levels (Fig. 2DeH).
3.3. Sitagliptin exerts no inﬂuence on integrin b1 or VEGF-R1 levels
in endothelial cells
VEGF-A serves biologically signiﬁcant roles through the VEGF-
receptor (-R) 2 in endothelial cells, and VEGF-A binding to VEGF-
R1 exerts a dominant negative effect on VEGF-A-mediated sur-
vival signaling of endothelial cells [17]. EndMT is negatively regu-
lated by VEGF-A/VEGF-R2 signaling; the VEGF-R1-mediated
trapping of VEGF-A results in a reduction of bioavailable VEGF-A,
inducing EndMT [18]. When the endothelial cells were stimulated
with TGF-b2, VEGF-R1 was induced, and VEGF-R2 was suppressed;Linagliptin restored TGF-b2-induced alterations in the VEGF-Rs,
whereas Sitagliptin did not (Fig. 3AeC). Integrin b1 is essential for
DPP-4-associated EndMT, and DPP-4 or integrin b1 deﬁciency
resulted in the inhibition of TGF-b2-stimulated heterodimer for-
mation of TGF-bRs and intracellular signal transduction [14]. This
study demonstrated that TGF-b2-induced integrin b1 protein levels
can be suppressed by Linagliptin but not by Sitagliptin (Fig. 3A, D).3.4. Linagliptin, but not Sitagliptin, can suppress DPP-4 homo-
dimer formation
Homo-dimer formation is essential for catalytic effects of DPP-4
[19]. To identify the molecular mechanisms of the differential ef-
fects between Linagliptin and Sitagliptin on EndMT-associated
proﬁbrotic signaling, we investigated the effects of each DPP-4 in-
hibitor on the homo-dimer formation of DPP-4 protein in endo-
thelial cells. We constructed two mammalian overexpression
vectors, pCMV-DPP-4-GFP and pCMV-Myc-DPP-4, to analyze the
homo-dimer formation of DPP-4 protein (Fig. 4A). When we
transfected pCMV-Myc-DPP-4 into endothelial cells, which could
form homo-dimers with either endogenous or overexpressed DPP-
4, there was no difference in the Myc protein level between the
transfected group and the Sitagliptin- or Linagliptin-treated cells
(Fig. 4B). However, our chemical crosslink experiment revealed that
Linagliptin treatment can signiﬁcantly decrease the homo-dimers
(~220 kDa) that consisted of Myc-DPP-4; Sitagliptin did not
inhibit the 220 kDa homo-dimer form of DPP-4 (Fig. 4B). Finally, we
performed the Duolink® in situ proximity ligation assay to further
Fig. 2. TGF-b2-induced EndMT and TGF-b signaling were not suppressed by Sitagliptin A: Western blot analysis of CD31 and aSMA in TGF-b2-treated (5 ng/ml) HMVECs with or
without Linagliptin (100 nM) or Sitagliptin (5 mM). Representative blot from 4 independent experiments are shown. BeC: Densitometric analysis of the CD31 and aSMA levels
normalized with actin. n ¼ 4 in each group were analyzed. Data are expressed as the means ± SEM in the graph. D: Western blot analysis of p-smad3 in TGF-b2-treated (5 ng/ml)
HMVECs with or without Linagliptin (100 nM) or Sitagliptin (5 mM). Representative blot from 4 independent experiments are shown. E: Densitometric analysis of the p-smad3 level
normalized with smad3. F: Western blot analysis of TGF-bR1 and TGF-bR2 in TGF-b2-treated (5 ng/ml) HMVECs with or without Linagliptin (100 nM) or Sitagliptin (5 mM).
Representative blot from 4 independent experiments are shown. GeH: Densitometric analysis of the TGF-bR1 and TGF-bR2 level normalized with actin.
Fig. 3. Sitagliptin did not regulate integrin b1, VEGF-R1/R2 or miR-29s levels in endothelial cells A: Western blot analysis of VEGF-R1, VEGF-R2 and integrin b1 in TGF-b2-treated
(5 ng/ml) HMVECs with or without Linagliptin (100 nM) or Sitagliptin (5 mM). Representative blot from 4 independent experiments are shown. BeD: Densitometric analysis of the
VEGF-R1, VEGF-R2 and integrin b1 levels normalized with actin. n ¼ 4 in each group analyzed. Data are expressed as the means ± SEM in the graph.
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proximity between Myc-DPP-4 and DPP-4-GFP in the TGF-b2-
treated cells, Linagliptin signiﬁcantly suppressed the formation of
Myc-DPP-4 and DPP-4-GFP homo-dimers, whereas Sitagliptin did
not (Fig. 4C, D; Supplementary Fig. 1). These results further
conﬁrmed that Linagliptin inhibited the homo-dimer formation of
DPP-4 in endothelial cells, whereas Sitagliptin did not; this differ-
ence between the two gliptins could explain their diverse effects on
endothelial cell biology.
4. Discussion
We preliminarily conﬁrmed that both Sitagliptin and Linagliptin
exhibited DPP-4 suppression in a cell-free system, whereas in
endothelial cells, only Linagliptin suppressed DPP-4 protein levels
and activity. Furthermore, TGF-b2-induced EndMT, integrinb1, TGF-
bR1/2, suppression of VEGF-R1, and induction of VEGF-R2 were all
inhibited by Linagliptin; Sitagliptin did not exhibit any of the above
effects in endothelial cells. Linagliptin also suppressed DPP-4 30UTR
activity associated with the restoration of microRNA 29 levels;
Sitagliptin did not inﬂuence either the DPP-4 30UTR activity or
microRNA 29 levels. Furthermore, our Duolink and chemical
crosslink results revealed that the homo-dimer formation of DPP-4
was suppressed by Linagliptin but not by Sitagliptin. These data
indicated that each DPP-4 inhibitor may have unique drug-speciﬁc
effects.
DPP-4 is a cell surface aminopeptidase that exerts diverse bio-
logical activities, such as protease activity, association withadenosine deaminase, interactionwith the extracellular matrix, cell
surface co-receptor activity mediating viral entry, and regulation of
intracellular signal transduction, coupled with the control of cell
migration and proliferation [20e24]. The enzymatic activity of DPP-
4 is believed to be independent of its protein-binding function [25].
The involvement of DPP-4 in many aspects of metabolism raises the
possibility that its inhibition may play a role in numerous systems,
a fact that may affect the efﬁcacy, safety and tolerability of DPP-4
inhibitors [9]. In the present study, Sitagliptin and Linagliptin
were observed to have different effects on endothelial cell biology,
indicating that each DPP-4 inhibitor has unique drug-speciﬁc ef-
fects. Some possible reasons for differences between the DPP-4
inhibitors may include the following: 1) DPP-4 inhibitors can be
divided based on their structure into those that mimic the dipep-
tide structure of DPP-4 substrates and those that are non-
peptidomimetic. Sitagliptin belongs to the peptidomimetic family,
which has a triazolopiperazine-based structure, and Linagliptin
belongs to the non-peptidomimetic family, which includes
imidazole-based inhibitors [26,27]; 2) Linagliptin is with a logD of
0.4 at pH 7.4 slightly more lipophilic than Sitagliptin (logD ¼ 0.2 at
pH 7.4) [28,29]. Sitagliptin exhibits pH-dependent aqueous solu-
bility, it is soluble in water and N,N-dimethyl formamide and
slightly soluble in methanol [30]; 3) Recently, Nabeno et al. divided
DPP-4 inhibitors into three classes based on their binding subsites
[31]. Linagliptin belongs to the second class and interacts with S1
and S2 subsites but also with the additional S01 subsite, where
Tyr547 is located; among the DPP-4 inhibitors, only Linagliptin
binds to the S02 subsite. Sitagliptin belongs to the third class and
Fig. 4. Linagliptin, but not Sitagliptin, can suppress DPP-4 homo-dimer formation in endothelial cells. A: Western blot analysis of DPP-4, Myc and GFP in HMVECs after being
transfected with pCMV-DPP-4-GFP or pCMV-Myc-DPP-4 cDNA. B: Chemical crosslink analysis of Myc in HMVECs after being transfected with pCMV-Myc-DPP-4 cDNA. After protein
crosslinked with glutaraldehyde, a Western blot was performed for the Myc antibody. No-crosslink protein was used as the negative control. C: Duolink in situ analysis for Myc/GFP
in HMVECs after being transfected with pCMV-DPP-4-GFP or pCMV-Myc-DPP-4 cDNA with or without TGF-b2 (5 ng/ml). For each slide, 1260magniﬁcation images were obtained
by confocal microscope from 10 different areas. Scale bar: 50 mm in each panel. D: Quantiﬁcation of the Duolink in situ analysis. Combination sites of the Myc-DPP-4/DPP-4-GFP in
the cells were counted; 10 different areas, including 100 cells, were evaluated in 1260 images. The data in the graph in the ﬁgure are expressed as the means ± SEM. Linagliptin
(100 nM) or Sitagliptin (5 mM).
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DPP-4 is required for its activity, Tyr547, Glu205 and Glu206 from
the propeller loop are critical for the dimerization and thus the
enzymatic activity of DPP-4 [32e34]. To conﬁrm whether DPP-4
homo-dimer formation on endothelial cells is important to
explain the difference between Linagliptin and Sitagliptin, we
performed both the chemical crosslink method and Duolink prox-
imity ligation assay. Our results revealed that the homo-dimer of
DPP-4 protein was inhibited by Linagliptin but not by Sitagliptin.
This difference might be the reason why displaying the different
properties of the two drugs. DPP-4 is expressed ubiquitously and
found in many cell types, including endothelial cells and epithelial
cells [4]. Therefore, different DPP-4 inhibitors may display diverse
biological inﬂuences depending on the cell type.
In conclusion, we found that Linagliptin and Sitagliptin could be
differentiated by their effects on EndMT-associated proﬁbrotic
signaling, including DPP-4 protein level regulation. The differences
between these two drugs were likely based on their ability to
inhibit DPP-4 protein homo-dimer formation and the subsequent
induction of the DPP-4-induced signaling cascade relevant for
EndMT.Disclosures
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